The historic rise of Viagra has consistently remained a benchmark of pharmaceutical success, yet its legacy within the broader sector now raises questions about long-term gains. Generic versions are diminishing patent protection , causing concerns that supporting companies heavily reliant to Viagra's previous standing could be a dangerous strategy,